Clinical trial
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic…
NCT00016107 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016107 |
|---|---|
| Title | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer |
| Official title | A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab (IND # 7921, NSC # 704865) In Men With Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | estramustine phosphate sodium, docetaxel, bevacizumab, laboratory biomarker analysis |
| Enrollment | 72 |
| Start date | Jun 1, 2001 |
| Primary completion | Feb 1, 2007 |
| First posted | Jun 10, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: